Literature DB >> 26659914

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.

Annemiek Broijl1, Marie-José Kersten2, Wendimagegn Ghidey Alemayehu3, Mark-David Levin4, Okke de Weerdt5, Edo Vellenga6, Ellen Meijer7, Shulamit Wittebol8, Bea C Tanis9, Petra B Cornelisse3, Marian Stevens-Kroef10, Gerard M J Bos11, Pierre W Wijermans12, Henk Lokhorst7, Pieter Sonneveld13.   

Abstract

Entities:  

Keywords:  VRD; escalated dose; first relapse; multiple myeloma

Mesh：

Substances：

Year:  2015        PMID： 26659914      PMCID： PMC5004394          DOI： 10.3324/haematol.2015.132431

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

Authors:  Antonio Palumbo; Maria Teresa Ambrosini; Giulia Benevolo; Patrizia Pregno; Norbert Pescosta; Vincenzo Callea; Clotilde Cangialosi; Tommaso Caravita; Fortunato Morabito; Pellegrino Musto; Sara Bringhen; Patrizia Falco; Ilaria Avonto; Federica Cavallo; Mario Boccadoro
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

3.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D Cavenagh; Anthony L Boral; Dixie-Lee Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel
Journal:  Br J Haematol       Date:  2009-01-16       Impact factor: 6.998

4.  The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.

Authors:  E Terpos; E Kastritis; M Roussou; D Heath; D Christoulas; N Anagnostopoulos; E Eleftherakis-Papaiakovou; K Tsionos; P Croucher; M A Dimopoulos
Journal:  Leukemia       Date:  2008-09-04       Impact factor: 11.528

5.  Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.

Authors:  Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Ann Hematol       Date:  2009-11-18       Impact factor: 3.673

6.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Authors:  Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

7.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

8.  The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

Authors:  Stefania Ciolli; Franco Leoni; Cinzia Casini; Carla Breschi; Valeria Santini; Alberto Bosi
Journal:  Br J Haematol       Date:  2008-04-10       Impact factor: 6.998

9.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

Review 10.  New drugs for myeloma.

Authors:  Paul G Richardson; Constantine Mitsiades; Robert Schlossman; Nikhil Munshi; Kenneth Anderson
Journal:  Oncologist       Date:  2007-06
View more
  2 in total

1.  Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain.

Authors:  Malik Bechakra; Mariska D Nieuwenhoff; Joost van Rosmalen; Geert Jan Groeneveld; Marjan Scheltens-de Boer; Pieter Sonneveld; Pieter A van Doorn; Chris I de Zeeuw; Joost Lm Jongen
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.395

Review 2.  IκBζ: an emerging player in cancer.

Authors:  Marie Willems; Nadège Dubois; Lucia Musumeci; Vincent Bours; Pierre A Robe
Journal:  Oncotarget       Date:  2016-10-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.